Michael King

Michael King

No open positions remaining
65 year
Finance
Health Technology
Consumer Services

Profile

Mr. Michael G.
King
, Jr., is a Director of Research & Senior Biotechnology Analyst at Rodman & Renshaw LLC and a Chief Executive Officer at Oqory, Inc. Mr. King was previously employed as a Chief Financial Officer & Executive Vice President by SAB Biotherapeutics, Inc., a Managing Director & Head of Healthcare Research by EF Hutton LLC, a Managing Director & Senior Healthcare Analyst by H.
C.
Wainwright & Co. LLC, a Senior Analyst by JMP Securities LLC, a Managing Director & Senior Analyst by Dawson James Securities, Inc., an Analyst by Rodman & Renshaw LLC (Old), a SVP-Corporate Development & Communication by ZIOPHARM Oncology, Inc., a Managing Director-Equity Research by Wedbush Securities, Inc., a Managing Director by Merriman Curhan Ford & Co., a Senior Analyst by Banc of America Securities LLC, a Senior Analyst by Robertson Stephens, Inc., a Senior Analyst by Vector Securities LLC, a Senior Analyst by Dillon, Read & Co., Inc., a Senior Vice President by Alex.
Brown & Sons, Inc., a Vice President by Hambrecht & Quist LLC, and a Vice President by Kidder, Peabody & Co., Inc. He received his undergraduate degree from Baruch College.

Michael King active positions

CompaniesPositionStart
Director of Research - Equity 01/01/2026

Former positions of Michael King

CompaniesPositionEnd
SAB BIOTHERAPEUTICS, INC. Director of Finance/CFO 04/06/2024
Analyst-Equity 01/05/2023
Analyst-Equity 06/06/2018
Director of Research - Equity 31/12/2012
Analyst-Equity 01/09/2012
See the detail of Michael King's experience

Training of Michael King

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

95

1st degree connections

18

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies18

Finance

Finance

Finance

Finance

Finance

Finance

Finance

Finance

Finance

Finance

Consumer Services

Health Technology

Finance

Finance

Finance

Finance

Finance

Health Technology

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!